IDEAYA Biosciences Inc at Citi BioPharma Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Mohit Bansal - CitiGroup Inc. - Analyst : Yes, so maybe I'll start with Susan. You (inaudible) you're doing great, actually. So you could have conducted the whole panel. So now I would like to -- especially questions on your (inaudible) program, which actually you have an interim data readout in 2021. And we know that enough with (inaudible) alterations, patients have a really poor survival, eight months or so with standard of care. When we see the data in 2021. Susan, can you please help us frame what sort of signal -- improved signal or improvement we need to see or you need to see to advance the drug into more controlled setting or expand the program here? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 09, 2020 / 3:40PM, IDYA.OQ - IDEAYA Biosciences Inc at Citi BioPharma Conference (Virtual)

Question: Mohit Bansal - CitiGroup Inc. - Analyst : Got it. This is very helpful. And maybe, [Yu], a question for you. I mean, you have been developing your synthetic lethality platform for quite a while. And now with this whole platform, synthetic lethality therapy as an approach to treat cancers is coming to the limelight. i mean there are multiple companies trying to do something similar to you as well here. Could you briefly touch upon what are the unique features of your platform that help IDEAYA stand apart from the peers. And as a field, where do you think the field is going? I mean, do you -- how do you think this field will evolve over time?

Question: Mohit Bansal - CitiGroup Inc. - Analyst : Great. I'll pass the baton over to Joel.